Transfusion Strategy in Myocardial Infarction and Anemia

Mirza S Khan,John A Spertus,Paul S Chan

DOI: https://doi.org/10.1056/nejmc2400982

IF: 158.5

2024-03-07

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 10, Page 960-962, March 2024.

medicine, general & internal

What problem does this paper attempt to address?

Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia

Jeffrey L Carson,Maria Mori Brooks,Paul C Hébert,Shaun G Goodman,Marnie Bertolet,Simone A Glynn,Bernard R Chaitman,Tabassome Simon,Renato D Lopes,Andrew M Goldsweig,Andrew P DeFilippis,J Dawn Abbott,Brian J Potter,Francois Martin Carrier,Sunil V Rao,Howard A Cooper,Shahab Ghafghazi,Dean A Fergusson,William J Kostis,Helaine Noveck,Sarang Kim,Meechai Tessalee,Gregory Ducrocq,Pedro Gabriel Melo de Barros E Silva,Darrell J Triulzi,Caroline Alsweiler,Mark A Menegus,John D Neary,Lynn Uhl,Jordan B Strom,Christopher B Fordyce,Emile Ferrari,Johanne Silvain,Frances O Wood,Benoit Daneault,Tamar S Polonsky,Manohara Senaratne,Etienne Puymirat,Claire Bouleti,Benoit Lattuca,Harvey D White,Sheryl F Kelsey,P Gabriel Steg,John H Alexander,MINT Investigators

DOI: https://doi.org/10.1056/NEJMoa2307983

2023-12-28

Abstract:Background: A strategy of administering a transfusion only when the hemoglobin level falls below 7 or 8 g per deciliter has been widely adopted. However, patients with acute myocardial infarction may benefit from a higher hemoglobin level. Methods: In this phase 3, interventional trial, we randomly assigned patients with myocardial infarction and a hemoglobin level of less than 10 g per deciliter to a restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g per deciliter) or a liberal transfusion strategy (hemoglobin cutoff, <10 g per deciliter). The primary outcome was a composite of myocardial infarction or death at 30 days. Results: A total of 3504 patients were included in the primary analysis. The mean (±SD) number of red-cell units that were transfused was 0.7±1.6 in the restrictive-strategy group and 2.5±2.3 in the liberal-strategy group. The mean hemoglobin level was 1.3 to 1.6 g per deciliter lower in the restrictive-strategy group than in the liberal-strategy group on days 1 to 3 after randomization. A primary-outcome event occurred in 295 of 1749 patients (16.9%) in the restrictive-strategy group and in 255 of 1755 patients (14.5%) in the liberal-strategy group (risk ratio modeled with multiple imputation for incomplete follow-up, 1.15; 95% confidence interval [CI], 0.99 to 1.34; P = 0.07). Death occurred in 9.9% of the patients with the restrictive strategy and in 8.3% of the patients with the liberal strategy (risk ratio, 1.19; 95% CI, 0.96 to 1.47); myocardial infarction occurred in 8.5% and 7.2% of the patients, respectively (risk ratio, 1.19; 95% CI, 0.94 to 1.49). Conclusions: In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days. However, potential harms of a restrictive transfusion strategy cannot be excluded. (Funded by the National Heart, Lung, and Blood Institute and others; MINT ClinicalTrials.gov number, NCT02981407.).
Restrictive Versus Liberal Transfusion in Symptomatic Coronary Artery Disease and Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

Sahib Singh,Udaya S. Tantry,Kevin Bliden,Paul A. Gurbel,Eliano Navarese,Aakash Garg

DOI: https://doi.org/10.1097/mjt.0000000000001762

2024-11-20

American Journal of Therapeutics

Abstract:In patients with coronary artery disease (CAD) and/or myocardial infarction (MI), anemia is associated with an increased risk of adverse cardiovascular (CV) outcomes. Transfusion goals in such patients remain unclear.

pharmacology & pharmacy
Transfusion in Anemic Patients with Acute Coronary Syndromes: A Population-Based Cohort Study

Nikhil Mistry,C. David Mazer,Atul Sivaswamy,Olivia Haldenby,Peter C. Austin,Maneesh Sud,Gregory M.T. Hare,Nadine Shehata,Karim S. Ladha,Duminda N. Wijeysundera,Subodh Verma,Dennis T. Ko

DOI: https://doi.org/10.1016/j.cjca.2024.10.012

IF: 6.614

2024-10-21

Canadian Journal of Cardiology

Abstract:Background There is controversy surrounding the effectiveness of red blood cell (RBC) transfusion for treating anemia in patients hospitalized for acute coronary syndromes (ACS), particularly as hemoglobin levels (Hb) approach and drop below the range of moderate anemia. Methods This population-based cohort study followed all adults hospitalized for ACS who experienced an in-hospital nadir Hb between 6.0-8.9g/dL between April 1, 2012 to March 31, 2021 in Ontario, Canada. Patients were excluded if they underwent coronary artery bypass graft surgery or had history of dementia, palliative care, or long-term care. Transfused patients were compared to non-transfused patients. The primary outcome was a composite of all-cause death and hospitalization for myocardial infarction (MI) within 30-days of hospital discharge. Overlap propensity score weighting was used to account for confounding and to emphasize the comparison in patients for whom there is clinical equipoise. Results This study included 7,922 patients, of whom 3,498 were transfused and 4,424 were not transfused. In the propensity weighted cohort, the mean nadir Hb for each group was 7.75g/dL. The 30-day cumulative incidence rate for the primary outcome after application of propensity score weights was 28.6% in the transfusion group and 33.3% in the no-transfusion group (hazard ratio [HR]: 0.83, 95% confidence interval [CI] 0.75-0.91), which persisted at 1-year after hospital discharge and across sensitivity analyses. Conclusions In patients hospitalized for ACS who experience nadir Hb levels between 6.0-8.9g/dL, RBC transfusion was associated with a reduction in the composite event of all-cause death and hospitalization for MI within 30-days after hospital discharge.

cardiac & cardiovascular systems
Efficacy and safety of restrictive versus liberal blood transfusion strategies in acute myocardial infarction and anemia: a systematic review and meta-analysis of randomized controlled trials

Ahmed Mazen Amin,Karim Ali,Hossam Elbenawi,Alhassan Saber,Mohamed Abuelazm,Basel Abdelazeem

DOI: https://doi.org/10.1097/mca.0000000000001349

2024-02-26

Coronary Artery Disease

Abstract:Background Blood transfusion strategies in patients with acute myocardial infarction (AMI) and anemia are yet to be conclusively identified. Thus, we aim to assess the efficacy and safety of restrictive versus liberal blood transfusion strategies for AMI and anemia. Methods A systematic review and meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, web of science, SCOPUS, EMBASE, and Cochrane Central Register of Controlled Trials were performed through November 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD) with a 95% confidence interval (CI). (PROSPERO): ID: CRD42023490692. Results We included four RCTs with 4.325 patients. There was no significant difference between both groups regarding MACE whether at 30 days (RR: 0.93 with 95% CI [0.57–1.51], P = 0.76) or ≥ six months (RR: 1.17 with 95% CI [0.95–1.45], P = 0.14), all-cause mortality at 30 days (RR: 1.16 with 95% CI [0.95–1.40], P = 0.14) or ≥ six months (RR: 1.16 with 95% CI [0.88–1.53], P = 0.28). However, the liberal strategy was significantly associated with increased hemoglobin level change (MD: −1.44 with 95% CI [−1.68 to −1.20], P < 0.00001). However, the restrictive strategy was significantly associated with a lower incidence of acute lung injury (RR: 0.11 with 95% CI [0.02–0.60], P = 0.01). Conclusion There was no significant difference between the restrictive blood transfusion strategy and the liberal blood transfusion strategy regarding the clinical outcomes. However, restrictive blood transfusion strategy was significantly associated with a lower incidence of acute lung injury than liberal blood transfusion strategy.

cardiac & cardiovascular systems
Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia : A Target Trial Emulation Using MINT Trial Data

Gerard T Portela,Jeffrey L Carson,Sonja A Swanson,John H Alexander,Paul C Hébert,Shaun G Goodman,Philippe Gabriel Steg,Marnie Bertolet,Jordan B Strom,Dean A Fergusson,Tabassome Simon,Harvey D White,Howard A Cooper,J Dawn Abbott,Sunil V Rao,Bernard R Chaitman,Christopher B Fordyce,Renato D Lopes,Benoit Daneault,Maria M Brooks,MINT Investigators,MINT Investigators*

DOI: https://doi.org/10.7326/M24-0571

2024-10-01

Abstract:Background: The optimal hemoglobin threshold to guide red blood cell (RBC) transfusion for patients with acute myocardial infarction (MI) and anemia is uncertain. Objective: To estimate the efficacy of 4 individual hemoglobin thresholds (<10 g/dL [<100 g/L], <9 g/dL [<90 g/L], <8 g/dL [<80 g/L], and <7 g/dL [<70 g/L]) to guide transfusion in patients with acute MI and anemia. Design: Prespecified secondary analysis of the MINT (Myocardial Ischemia and Transfusion) trial using target trial emulation methods. (ClinicalTrials.gov: NCT02981407). Setting: 144 clinical sites in 6 countries. Participants: 3492 MINT trial participants with acute MI and a hemoglobin level below 10 g/dL. Intervention: Four transfusion strategies to maintain patients' hemoglobin concentrations at or above thresholds of 10, 9, 8, or 7 g/dL. Protocol exceptions were permitted for specified adverse clinical events. Measurements: Data from the MINT trial were leveraged to emulate 4 transfusion strategies and estimate per protocol effects on the composite outcome of 30-day death or recurrent MI (death/MI) and 30-day death using inverse probability weighting. Results: The 30-day risk for death/MI was 14.8% (95% CI, 11.8% to 18.4%) for a <10-g/dL strategy, 15.1% (CI, 11.7% to 18.2%) for a <9-g/dL strategy, 15.9% (CI, 12.4% to 19.0%) for a <8-g/dL strategy, and 18.3% (CI, 14.6% to 22.0%) for a <7-g/dL strategy. Absolute risk differences and risk ratios relative to the <10-g/dL strategy for 30-day death/MI increased as thresholds decreased, although 95% CIs were wide. Findings were similar and imprecise for 30-day death. Limitation: Unmeasured confounding may have persisted despite adjustment. Conclusion: The 30-day risks for death/MI and death among patients with acute MI and anemia seem to increase progressively with lower hemoglobin concentration thresholds for transfusion. However, the imprecision around estimates from this target trial analysis precludes definitive conclusions about individual hemoglobin thresholds. Primary funding source: National Heart, Lung, and Blood Institute.
Red Blood Cell Transfusion Strategies in Cardiovascular Interventions

Melissa Foglietta,Elena Bacigalupi,Francesco Radico,Jacopo Pizzicannella,Marianna Appignani,Federica De Donno,Patrizia Di Gregorio,Francesco Pelliccia,Marco Zimarino

DOI: https://doi.org/10.31083/j.rcm2507252

2024-07-08

Abstract:Acute coronary syndrome, cardiac surgery, and cardiac structural interventions are among the most common situations leading to allogeneic red blood cell consumption due to the prevalence of bleeding and anemia. The wide variability in the use of transfusions derives from the current lack of data, and the absence of strong evidence and clear guideline recommendations. The current approach is to avoid unnecessary blood transfusions and limit their use to life-saving conditions; this conservative strategy derives from often controversial and inconclusive results of observational and randomized studies where liberal and restricted red blood transfusion strategies seemed to have similar outcomes. The pivotal question for future research lies in elucidating whether blood transfusions function as an active participant or merely a catalyst in amplifying adverse events. The present review aims to summarize the current literature data and critically analyze the available evidence for red blood transfusions in cardiac interventions.
A liberal blood transfusion strategy is safe in patients with myocardial infarction, anemia, and heart failure: lessons from MINT

A M Goldsweig,W Kostis,B M Herbert,J Benatar,C Bouleti,E L Figueiredo,T Huynh,B Potter,D B Sims,J B Strom,M Torosoff,S Vallurupalli,J L Carson,M M Brooks,J H Alexander

DOI: https://doi.org/10.1093/eurheartj/ehae666.1619

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background In patients with acute myocardial infarction (MI) and anemia, the Myocardial Ischemia and Transfusion (MINT) trial found a trend toward increased 30-day death or recurrent MI with a restrictive compared with a liberal blood transfusion strategy. Patients with and without heart failure (HF) may respond differently to blood transfusion. Purpose To characterize the effects of restrictive vs. liberal transfusion strategies on clinical outcomes in patients with MI and anemia with and without baseline HF. Methods In the MINT trial, 3504 patients with MI and hemoglobin <10 g/dL were randomized to restrictive (7-8 g/dL) or liberal (10 g/dL) transfusion thresholds. We compared outcomes between patients with and without baseline HF, defined as any history of HF, acute HF, or baseline left ventricular ejection fraction (LVEF) <45%. Outcomes included death or incident HF, death or recurrent MI, death, and incident HF, all at 30 days. Results Compared with patients without baseline HF (n=1633), patients with baseline HF (overall n=1871 (history of HF n=1066, acute HF n=780, LVEF <45% n= 1099) were older, more frequently male and Black, and had higher rates of prior PCI, diabetes, and hypertension. In the restrictive strategy, patients with and without baseline HF received an average of 0.63 and 0.80 units of blood and had a median LOS of 6 and 4 days, respectively. In the liberal strategy, patients with and without baseline HF received an average of 2.44 and 2.49 units of blood and had a median LOS of 5 and 4 days, respectively. Patients with baseline HF had higher rates of death or incident HF (18.0% vs. 10.0%, risk ratio [RR]=1.79 [95% confidence interval {CI} 1.50-2.13]), death or recurrent MI (17.6% vs. 13.5%, RR=1.31 [95% CI 1.12-1.53]), and death (10.5% vs. 7.5%, RR 1.41 [95% CI 1.14-1.75]). Among patients with baseline HF, a restrictive transfusion strategy resulted in a trend toward an increase in death or HF and death or MI compared with a liberal transfusion strategy (Table, Figure). Among patients without baseline HF, the risk of incident HF was lower with restrictive than with liberal transfusion strategy. Conclusions Among patients with MI and anemia, a restrictive transfusion strategy resulted in a greater increase in death or HF, death or MI, and death in patients with baseline HF than in patients without baseline HF. A liberal transfusion strategy is safe for patients with MI and anemia, including those with prior or acute HF.TableFigure

cardiac & cardiovascular systems
Restrictive vs Liberal Blood Transfusions for Patients with Acute Myocardial Infarction and Anaemia by Heart Failure Status: An RCT Subgroup Analysis

Gregory Ducrocq,Marine Cachanado,Tabassome Simon,Etienne Puymirat,Gilles Lemesle,Benoit Lattuca,Albert Ariza-Solé,Johanne Silvain,Emile Ferrari,Jose R. Gonzalez-Juanatey,Manuel Martínez-Sellés,Thibault Lermusier,Pierre Coste,Gerald Vanzetto,Yves Cottin,Jean G. Dillinger,Gonzalo Calvo,Philippe Gabriel Steg,REALITY Investigators

DOI: https://doi.org/10.1016/j.cjca.2024.02.013

IF: 6.614

2024-02-01

Canadian Journal of Cardiology

Abstract:BACKGROUND: Red blood cell transfusion can cause fluid overload. We evaluated the interaction between heart failure (HF) at baseline and transfusion strategy on outcomes in acute myocardial infarction (AMI).METHODS: We used data from the randomized REALITY trial (https://www.CLINICALTRIALS: gov/study/NCT02648113), comparing restrictive versus liberal transfusion strategies in patients with AMI and anaemia. HF was defined as history of HF or Killip class > 1 at randomization. Primary outcome was major adverse cardiovascular events (MACE: composite of all-cause death, non-recurrent AMI, stroke, or emergency revascularization prompted by ischaemia) at 30 days.RESULTS: Among 658 randomized patients, 311 (47.3%) had HF. HF patients had higher rates of MACE at 30 days and 1 year, and higher rates of non-fatal new-onset HF. There was no interaction between HF and effect of randomized assignment on the primary outcome or non-fatal new-onset HF. A liberal transfusion strategy was associated with increased all-cause death at 30 days and at 1 year in HF patients (P<sub>interaction</sub> = 0.009 and P = 0.049, respectively). The main numerical difference in cause of death between restrictive and liberal strategies was death by HF at 30 days (4 vs 11).CONCLUSIONS: HF is frequent in AMI patients with anaemia and is associated with higher risk of MACE (including all-cause death) and non-fatal new-onset HF. While there was no interaction of HF with effect of transfusion strategy on MACE, a liberal transfusion strategy was associated with higher all-cause death that appears driven by a higher risk of early death due to HF.

cardiac & cardiovascular systems
Anemia and Red Blood Cell Transfusion in Aneurysmal Subarachnoid Hemorrhage

Luke A Terrett,Lauralyn McIntyre,Alexis F Turgeon,Shane W English

DOI: https://doi.org/10.1007/s12028-023-01815-0

Abstract:Anemia is very common in aneurysmal subarachnoid hemorrhage (aSAH), with approximately half of the aSAH patient population developing moderate anemia during their hospital stay. The available evidence (both physiologic and clinical) generally supports an association of anemia with unfavorable outcomes. Although aSAH shares a number of common mechanisms of secondary insult with other forms of acute brain injury, aSAH also has specific features that make it unique: an early phase (in which early brain injury predominates) and a delayed phase (in which delayed cerebral ischemia and vasospasm predominate). The effects of both anemia and transfusion are potentially variable between these phases, which may have unique considerations and possibly different risk-benefit profiles. Data on transfusion in this population are almost exclusively limited to observational studies, which suffer from significant heterogeneity and risk of bias. Overall, the results are conflicting, with the balance of the studies suggesting that transfusion is associated with unfavorable outcomes. The transfusion targets that are well established in other critically ill populations should not be automatically applied to patients with aSAH because of the unique disease characteristics of this population and the limited representation of aSAH in the clinical trials that established these targets. There are two upcoming clinical trials evaluating transfusion in aSAH that should help clarify specific transfusion targets. Until then, it is reasonable to base transfusion decisions on the current guidelines and use an individualized approach incorporating physiologic and clinical data when available.
Restrictive versus liberal blood transfusion strategies in patients with myocardial infarction and anemia: individual patient data meta-analysis of randomized trials

J Carson,D A Fergusson,H Noveck,R Mallick,S V Rao,T Simon,P G Steg,H A Cooper,S G Goodman,J H Alexander,S J Stanworth,M M Brooks,P A Hebert

DOI: https://doi.org/10.1093/eurheartj/ehae666.1406

IF: 39.3

2024-10-29

European Heart Journal

Abstract:Background There are insufficient data to guide the appropriate use of red blood cell transfusion in patients with anemia and acute myocardial infarction (MI). Purpose To combine individual patient data from randomized clinical trials evaluating restrictive versus liberal transfusion strategies in patients with acute MI and anemia to generate precise estimates of treatment effects. Methods We searched all major databases to identify trials comparing restrictive versus liberal transfusion strategies in patients with acute MI and anemia (Hgb < 10 g/dl). We included studies that allocated participants to a liberal transfusion strategy that maintained hemoglobin greater than 10 g/dL or a restrictive transfusion strategy in which transfusion was administered if hemoglobin concentration was less than 8 g/dL. The primary outcome was a composite of 30-day death or MI. Secondary outcomes included 30-day death, 30-day cardiac death, and 6-month death. One-stage individual patient data meta-analyses were performed using a multilevel generalized linear model accounting for the clustering of patients within trials. Results We included 4311 participants from four trials. The primary outcome occurred in 334 patients (15.4%) in the restrictive and 296 patients (13.8%) in the liberal strategy (relative risk (RR) 1.13, 95% confidence interval (CI), 0.97 to 1.30) (figure 1). Death at 30-days occurred in 201 patients (9.3%) in the restrictive and 174 patients (8.1%) in the liberal strategy (RR 1.15; 95% CI, 0.95 to 1.39). Cardiac death at 30 days occurred in 5.5% in the restrictive strategy compared to 3.7% in the liberal strategy (RR 1.47; 95% CI, 1.11 to 1.94). Heart failure and thromboembolism occurred slightly more frequently in the liberal transfusion strategy group. Death at six months was higher in the restrictive (20.5%) compared to the liberal strategy (19.1%) (hazard ratio (HR) 1.08; 95% CI 1.05 to 1.11) (figure 2). The HR for cardiac death at 6 months was higher with a restrictive than liberal strategy (HR 1.38; 95% CI 1.08 to 1.76). In contrast, the HR for non-cardiac death at 6 months was lower with a restrictive than a liberal transfusion strategy (HR 0.89; 95% CI 0.84 to 0.94). Adjustment for baseline characteristics minimally changed the relative risk. Results for subgroups were similar except in patients without a history of renal failure whose risk of death or MI was increased with a restrictive strategy (RR 1.19; 95% CI, 1.01 to 1.39). Conclusions Pooled data from randomized trials found no significant differences for the primary outcome 30-day death or MI, but risk of cardiac death at 30 days and all cause death at 6 months was higher with a restrictive transfusion strategy. Given most outcomes favored liberal transfusion, and the risks from liberal transfusion were low, it may be prudent to use a liberal transfusion strategy in patients with acute MI and anemia.

cardiac & cardiovascular systems
Anemia or Transfusion: Getting to the Heart of the Issue

Kevin M. Trentino,Kevin Murray,Aryeh Shander

DOI: https://doi.org/10.1213/ane.0000000000006779

IF: 6.627

2024-03-17

Anesthesia & Analgesia

Abstract:See Article, page 728 So, what really is more dangerous: anemia or transfusion? This thought-provoking question was raised over 10 years ago by Shander et al, 1 and is just as relevant today as it was back then. Red cell transfusions are independently associated with a wide range of unfavorable outcomes. 2 Preoperative anemia is also independently associated with a wide range of unfavorable outcomes. 3 In addition, the 2 are highly intertwined, with patients admitted with preoperative anemia up to 4 times more likely to receive a red cell transfusion when compared to patients not anemic, and some data demonstrating the 2 are synergistic, having an additive effect on outcomes. 4 , 5

anesthesiology
Hemoglobin-based Transfusion Strategies for Cardiovascular - and Other Diseases: Restrictive, Liberal, or Neither?

Charles Natanson,Willard N. Applefeld,Harvey G Klein

DOI: https://doi.org/10.1182/blood.2024025927

IF: 20.3

2024-09-19

Blood

Abstract:A "restrictive" red blood cell transfusion threshold, hemoglobin concentration <7-8 g/dL, has long been recommended for most hospitalized patients including anemic patients with stable cardiovascular disease (CVD). Although no threshold recommendation is given for acute coronary syndromes (ACS), recent evidence suggests that "liberal" rather than "restrictive" transfusion strategies are associated with significantly improved safety for hospitalized patients with stable CVD and/or ACS. This...

hematology
Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial

P Deharo,G Ducrocq,C Bode,M Cohen,T Cuisset,S R Mehta,C V Pollack,S D Wiviott,S V Rao,J W Jukema,A Erglis,T Moccetti,Y Elbez,P G Steg

DOI: https://doi.org/10.1016/j.ijcard.2020.06.020

2020-11-01

Abstract:Background: The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI). Methods: The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a time-varying covariate. The primary ischemic outcome was the composite of all-cause death or MI within 180 days of randomization. Subgroup analyses were performed according to pre-transfusion hemoglobin nadir and bleeding status. Results: 12,547 patients were enrolled. Among these, blood transfusion was used in 489 (3.9%) patients. Patients who received transfusion had a higher rate of death or MI (29.9% vs. 8.1%, p<0.01). This excess risk persisted after adjustment on GRACE score and nadir of hemoglobin (HR 3.36 95%CI 2.63-4.29 p<0.01). Subgroup analyses showed that blood transfusion was associated with a higher risk in patients without overt bleeding (adjusted HR 6.25 vs. 2.85; p-interaction 0.001) as well as in those with hemoglobin nadir > 9.0 g/dl (HR 4.01; p-interaction<0.0001). Conclusion: In patients with NSTEMI, blood transfusion was associated with an overall increased risk of ischaemic events. However, this was mainly driven by patients without overt bleeding and those hemoglobin nadir > 9.0g/dl. This suggests possible harm of transfusion in those groups.
RBC Transfusion Strategies in the ICU: A Concise Review

Casey A Cable,Seyed Amirhossein Razavi,John D Roback,David J Murphy

DOI: https://doi.org/10.1097/CCM.0000000000003985

Abstract:Objectives: To critically assess available high-level clinical studies regarding RBC transfusion strategies, with a focus on hemoglobin transfusion thresholds in the ICU. Data sources: Source data were obtained from a PubMed literature review. Study selection: English language studies addressing RBC transfusions in the ICU with a focus on the most recent relevant studies. Data extraction: Relevant studies were reviewed and the following aspects of each study were identified, abstracted, and analyzed: study design, methods, results, and implications for critical care practice. Data synthesis: Approximately 30-50% of ICU patients receive a transfusion during their hospitalization with anemia being the indication for 75% of transfusions. A significant body of clinical research evidence supports using a restrictive transfusion strategy (e.g., hemoglobin threshold < 7 g/dL) compared with a more liberal approach (e.g., hemoglobin threshold < 10 g/dL). A restrictive strategy (hemoglobin < 7 g/dL) is recommended in patients with sepsis and gastrointestinal bleeds. A slightly higher restrictive threshold is recommended in cardiac surgery (hemoglobin < 7.5 g/dL) and stable cardiovascular disease (hemoglobin < 8 g/dL). Although restrictive strategies are generally supported in hematologic malignancies, acute neurologic injury, and burns, more definitive studies are needed, including acute coronary syndrome. Massive transfusion protocols are the mainstay of treatment for hemorrhagic shock; however, the exact RBC to fresh frozen plasma ratio is still unclear. There are also emerging complimentary practices including nontransfusion strategies to avoid and treat anemia and the reemergence of whole blood transfusion. Conclusions: The current literature supports the use of restrictive transfusion strategies in the majority of critically ill populations. Continued studies of optimal transfusion strategies in various patient populations, coupled with the integration of novel complementary ICU practices, will continue to enhance our ability to treat critically ill patients.
Restrictive Versus Liberal Transfusion in Patients with Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the Myocardial Ischemia and Transfusion (MINT) Trial

Andrew P DeFilippis,J Dawn Abbott,Brandon M Herbert,Marnie H Bertolet,Bernard R Chaitman,Harvey D White,Andrew M Goldsweig,Tamar S Polonsky,Rajesh Gupta,Caroline Alsweiler,Johanne Silvain,Pedro G M de Barros E Silva,Graham S Hillis,Benoit Daneault,Meechai Tessalee,Mark A Menegus,Sunil V Rao,Renato D Lopes,Paul C Hébert,John H Alexander,Maria M Brooks,Jeffrey L Carson,Shaun G Goodman,MINT Investigators

DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.071208

IF: 37.8

2024-08-29

Circulation

Abstract:Background: The MINT trial raised concern for harm from a restrictive versus liberal transfusion strategy in patients with acute myocardial infarction (MI) and anemia. Type 1 and type 2 MI are distinct pathophysiological entities that may respond differently to blood transfusion. This analysis sought to determine if the effects of transfusion varied among patients with a type 1 or a type 2 MI and anemia. We hypothesized that the liberal transfusion strategy would be of greater benefit in type 2 than in type 1 MI. Methods: We compared rates of death or MI at 30 days in patients with type 1 (n=1460) and type 2 (n=1955) MI and anemia who were randomly allocated to a restrictive (threshold of 7 to 8 g/dL) or a liberal (threshold of 10 g/dL) transfusion strategy. Results: The primary outcome of death or MI was observed in 16% of type 1 MI and 15.4% of type 2 MI patients. The rate of death or MI was higher in patients with type 1 MI randomized to a restrictive (18.2%) versus liberal (13.2%) transfusion strategy (RR 1.32, 95% CI 1.04 - 1.67) with no difference observed between the restrictive (15.8% ) and liberal (15.1% ) transfusion strategies in patients with type 2 MI (RR 1.05 95% CI 0.85-1.29). The test for a differential effect of transfusion strategy by MI type was not statistically significant (P-interaction = 0.16). Conclusions: The concern for harm with a restrictive transfusion strategy in patients with acute MI and anemia raised in the MINT primary outcome manuscript may be more apparent in patients with type 1 than type 2 MI. Clinical trial registration: ClinicalTrials.gov number, NCT02981407.
Abstract 20556: Safety and Efficacy of Intracoronary Hypoxia-PrecondItioned Bone Marrow Mononuclear Cells Administration for Acute Myocardial Infarction Patients

Xin Yang Hu,Xin Huang,Qian Yang,Lihan Wang,Jianzhong Sun,Hongwei Zhan,Jianjing Lin,Zhaoxia Pu,Jun Jiang,Yong Sun,Xianbao Liu,Xialjie Xie,Xia Yu,Zexin Chen,Hung-Fat Tse

DOI: https://doi.org/10.1161/circ.130.suppl_2.20556

IF: 37.8

2014-01-01

Circulation

Abstract:IMPORTANCE: Cell therapy has been a potential approach for ST-segment elevation acute myocardial infarction (STEMI). To improve the therapeutic oucome, the safety and efficacy of hypoxia-preconditioned (H-) bone marrow mononuclear cells (BMCs) in AMI patients need further evaluation. OBJECTIVE: To investigate the safety and efficacy of H-BMCs therapy in AMI patients. DESIGN: A phase 1, randomized and blinded study (February, 2011~ March, 2012) with one-year of follow-up. SETTING: A single center for hospitalized care. PARTICIPANTS: 22 Patients with an acute ST elevation myocardial infarction were recruited and randomized to two groups: normoxia BMCs (N-, n=11) and H-BMCs (n=11). INTERVENTIONS: Intracoronary infusion of H-BMCs or N-BMCs within 5-7 days after treatment with percutaneous transluminal coronary intervention (PCI). Patients were similarly treated by a stop-flow technique through an over-the-wire balloon catheter. MAIN OUTCOMES AND MEASURES: Primary endpoint was Treatment-emergent 30-day serious adverse event rate defined as a composite of death, MI, sustained ventricular tachycardia, stroke, hospitalization for worsening heart failure and revascularization. Secondary endpoints were change of myocardium perfusion, global left ventricular ejection fraction and left ventricular volumes. RESULTS: The primary endpoint events was none for N-BMCs and 9.1% (95% CI, 0.2%-41.3%) for H-BMCs. There was significant increase in the change of LVEF of H-BMCs group at 6 month. The change of end diastolic volume (EDV) and end systolic volume (ESV) in H-BMCs at 12 month were significantly decreased. Ratio of myocardium perfusion defect by Single-Photon Emission Computed Tomography (SPECT) was significantly reduced in H-BMCs group at 6 months, and score of myocardium perfusion defect by SPECT was significantly reduced than that of baseline in H-BMCs group at 6 and 12 months, unlike N- group. CONCLUSIONS AND RELEVANCE: Intracoronary infusion with H-BMCs appeared to be safe and effective for patients with AMI. Although the sample size precludes a definitive statement about safety and efficacy, these results provide the basis for larger studies to provide definitive evidence about safety and to assess efficacy of this new therapeutic approach.
Liberal versus restrictive transfusion strategies in acute myocardial infarction: a systematic review and comparative frequentist and Bayesian meta-analysis of randomized controlled trials

Rayan Braïk,Safa Jebali,Pierre-Louis Blot,Julia Egbeola,Arthur James,Jean-Michel Constantin

DOI: https://doi.org/10.1186/s13613-024-01376-1

IF: 10.318

2024-09-30

Annals of Intensive Care

Abstract:The transfusion strategy in the acute phase of myocardial infarction (AMI) remains a debated topic with non-standardized guidelines. This study aimed to evaluate the impact of liberal versus restrictive transfusion strategies on mortality during AMI.

critical care medicine
Anemia and red blood cell transfusion in neurocritical care

Andreas H Kramer,David A Zygun

DOI: https://doi.org/10.1186/cc7916

IF: 15.1

2009-01-01

Critical Care

Abstract:IntroductionAnemia is one of the most common medical complications to be encountered in critically ill patients. Based on the results of clinical trials, transfusion practices across the world have generally become more restrictive. However, because reduced oxygen delivery contributes to 'secondary' cerebral injury, anemia may not be as well tolerated among neurocritical care patients.MethodsThe first portion of this paper is a narrative review of the physiologic implications of anemia, hemodilution, and transfusion in the setting of brain-injury and stroke. The second portion is a systematic review to identify studies assessing the association between anemia or the use of red blood cell transfusions and relevant clinical outcomes in various neurocritical care populations.ResultsThere have been no randomized controlled trials that have adequately assessed optimal transfusion thresholds specifically among brain-injured patients. The importance of ischemia and the implications of anemia are not necessarily the same for all neurocritical care conditions. Nevertheless, there exists an extensive body of experimental work, as well as human observational and physiologic studies, which have advanced knowledge in this area and provide some guidance to clinicians. Lower hemoglobin concentrations are consistently associated with worse physiologic parameters and clinical outcomes; however, this relationship may not be altered by more aggressive use of red blood cell transfusions.ConclusionsAlthough hemoglobin concentrations as low as 7 g/dl are well tolerated in most critical care patients, such a severe degree of anemia could be harmful in brain-injured patients. Randomized controlled trials of different transfusion thresholds, specifically in neurocritical care settings, are required. The impact of the duration of blood storage on the neurologic implications of transfusion also requires further investigation.

critical care medicine
Impact of anemia on outcomes and resource utilization in patients with myocardial infarction: A national database analysis

Aravdeep S. Jhand,Waiel Abusnina,Hyo Jung Tak,Arslan Ahmed,Mahmoud Ismayl,S. Elissa Altin,Matthew W. Sherwood,John H. Alexander,Sunil V. Rao,J. Dawn Abbott,Jeffrey L. Carson,Andrew M. Goldsweig

DOI: https://doi.org/10.1016/j.ijcard.2024.132111

IF: 4.039

2024-05-02

International Journal of Cardiology

Abstract:Background Although anemia is common in patients with myocardial infarction (MI), management remains controversial. We quantified the association of anemia with in-hospital outcomes and resource utilization in patients admitted with MI using a large national database. Methods All hospitalizations with a primary diagnosis code for acute MI in the National Inpatient Sample (NIS) between 2014 and 2018 were identified. Among these hospitalizations, patients with anemia were identified using a secondary diagnosis code. Data on demographic and clinical variables were collected. Outcomes of interest included in-hospital adverse events, length of stay (LOS), and total cost. Multivariable logistic regression and generalized linear models were used to evaluate the relationship between anemia and outcomes. Results Among 1,113,181 MI hospitalizations, 254,816 (22.8%) included concomitant anemia. Anemic patients were older and more likely to be women. After adjustment for demographics and comorbidities, anemia was associated with higher mortality (7.1 vs. 4.3%; odds ratio 1.09; 95% confidence interval [CI] 1.07–1.12, p < 0.001). Anemia was also associated with a mean of 2.71 days longer LOS (average marginal effects [AME] 2.71; 95% CI 2.68–2.73, p < 0.05), and 9703, 95% CI 9829, p < 0.05). Anemic patients who received blood transfusions had higher mortality as compared with those who did not (8.2% vs. 7.0, p < 0.001). Conclusion In MI patients, anemia was associated with higher in-hospital mortality, adverse events, total cost, and length of stay. Transfusion was associated with increased mortality, and its role in MI requires further research.

cardiac & cardiovascular systems
Device-Based Approaches Targeting Cardioprotection in Myocardial Infarction: The Expanding Armamentarium of Innovative Strategies

Francisco José Romeo,Renata Mazurek,Tomoki Sakata,Spyros A Mavropoulos,Kiyotake Ishikawa

DOI: https://doi.org/10.1161/JAHA.122.026474

2022-12-06

Abstract:Coronary reperfusion therapy has played a pivotal role for reducing mortality and heart failure after acute myocardial infarction. Although several adjunctive approaches have been studied for reducing infarct size further, both ischemia-reperfusion injury and microvascular obstruction are still major contributors to both early and late clinical events after acute myocardial infarction. The progress in the field of cardioprotection has found several promising proof-of-concept preclinical studies. However, translation from bench to bedside has not been very successful. This comprehensive review discusses the importance of infarct size as a driver of clinical outcomes post-acute myocardial infarction and summarizes recent novel device-based approaches for infarct size reduction. Device-based interventions including mechanical cardiac unloading, myocardial cooling, coronary sinus interventions, supersaturated oxygen therapy, and vagal stimulation are discussed. Many of these approaches can modify ischemic myocardial biology before reperfusion and offer unique opportunities to target ischemia-reperfusion injury.

Transfusion Strategy in Myocardial Infarction and Anemia

Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia

Restrictive Versus Liberal Transfusion in Symptomatic Coronary Artery Disease and Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

Transfusion in Anemic Patients with Acute Coronary Syndromes: A Population-Based Cohort Study

Efficacy and safety of restrictive versus liberal blood transfusion strategies in acute myocardial infarction and anemia: a systematic review and meta-analysis of randomized controlled trials

Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia : A Target Trial Emulation Using MINT Trial Data

Red Blood Cell Transfusion Strategies in Cardiovascular Interventions

A liberal blood transfusion strategy is safe in patients with myocardial infarction, anemia, and heart failure: lessons from MINT

Restrictive vs Liberal Blood Transfusions for Patients with Acute Myocardial Infarction and Anaemia by Heart Failure Status: An RCT Subgroup Analysis

Anemia and Red Blood Cell Transfusion in Aneurysmal Subarachnoid Hemorrhage

Restrictive versus liberal blood transfusion strategies in patients with myocardial infarction and anemia: individual patient data meta-analysis of randomized trials

Anemia or Transfusion: Getting to the Heart of the Issue

Hemoglobin-based Transfusion Strategies for Cardiovascular - and Other Diseases: Restrictive, Liberal, or Neither?

Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial

RBC Transfusion Strategies in the ICU: A Concise Review

Restrictive Versus Liberal Transfusion in Patients with Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the Myocardial Ischemia and Transfusion (MINT) Trial

Abstract 20556: Safety and Efficacy of Intracoronary Hypoxia-PrecondItioned Bone Marrow Mononuclear Cells Administration for Acute Myocardial Infarction Patients

Liberal versus restrictive transfusion strategies in acute myocardial infarction: a systematic review and comparative frequentist and Bayesian meta-analysis of randomized controlled trials

Anemia and red blood cell transfusion in neurocritical care

Impact of anemia on outcomes and resource utilization in patients with myocardial infarction: A national database analysis

Device-Based Approaches Targeting Cardioprotection in Myocardial Infarction: The Expanding Armamentarium of Innovative Strategies